Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
137M
-
Number of holders
-
23
-
Total 13F shares, excl. options
-
1.92M
-
Shares change
-
+51.4K
-
Total reported value, excl. options
-
$2.24M
-
Value change
-
+$59.7K
-
Number of buys
-
11
-
Number of sells
-
-5
-
Price
-
$1.17
Significant Holders of Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD) as of Q3 2023
23 filings reported holding LUCD - Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share as of Q3 2023.
Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD) has 23 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.92M shares
of 137M outstanding shares and own 1.4% of the company stock.
Largest 10 shareholders include LUMINUS MANAGEMENT LLC (875K shares), VANGUARD GROUP INC (326K shares), Nantahala Capital Management, LLC (158K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (135K shares), GEODE CAPITAL MANAGEMENT, LLC (132K shares), Ayrton Capital LLC (73.9K shares), CITADEL ADVISORS LLC (36.4K shares), Verition Fund Management LLC (36.2K shares), Geneos Wealth Management Inc. (33.9K shares), and LPL Financial LLC (28.4K shares).
This table shows the top 23 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.